G1 THERAPEUTICS, INC.
GTHX · NASDAQ
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
ESG Scores
Overall ESG3.9
Environmental2.6
Social3.3
Governance6.1
Gender Diversity
Female Directors0.25%
Female Executives0.453257790368272%